EMA to Review Samsung Bioepis' Bevacizumab Biosimilar, SB8
Samsung Bioepis has announced that the European Medicines Agency (EMA) has accepted for review its market authorization application for SB8, a proposed bevacizumab biosimilar referencing Avastin.
Samsung Bioepis has announced that the European Medicines Agency (EMA) has accepted for review its market authorization application for SB8, a proposed bevacizumab biosimilar referencing Avastin.
The biosimilar was studied in a phase 3 clinical trial in 763 patients with metastatic or recurrent nonsquamous, non—small cell lung cancer (NSCLC). The study, which was completed in October 2018, comprised 2 arms: In each, patients were treated with either the reference Avastin or SB8 in combination with carboplatin and paclitaxel. The primary outcome measure was best objective response rate by week 24. Pharmacokinetics and immunogenicity were also compared between the proposed biosimilar and its reference.
Samsung Bioepis has not yet published the results of the trial.
If the biosimilar is approved, it will join Amgen’s Mvasi and Pfizer’s Zirabev among the ranks of EMA-authorized biosimilar bevacizumab products, and it will be commercialized in Europe by Samsung Bioepis’ partner, MSD (known as Merck in the US and Canadian markets).
The drug is also part of an agreement with 3SBio to commercialize several biosimilars in mainland China; if the drug is approved in the Chinese market, the companies will focus on sales of the biosimilar in the indications of NSCLC and metastatic colon cancer, which have high incidence rates in China.
Among Samsung Bioepis’ other biosimilar assets under development are SB11, a biosimilar ranibizumab referencing Lucentis, which is currently in a phase 3 trial in 705 patients with neovascular age-related macular degeneration, and SB12, a biosimilar eculizumab referencing Soliris, which recently completed a phase 1 clinical trial in 240 healthy volunteers.
The company is also branching out in the development of novel biologics; SB26, a novel ulinastatin-Fc fusion protein that is intended to treat gastrointestinal diseases, is currently in a phase 1 clinical trial in 58 healthy volunteers to explore the safety, tolerability, and pharmacokinetics of the product.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
